Pancreatic Cancer Research

ResearcherFred and Pamela Buffett Cancer CenterActive in the last 2 years

Parthasarathy Seshacharyulu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2348-3901; OpenAlex author ID A5001576318. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
80
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 4 papers · 2016: 2 papers · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: 4 papers · 2022: 5 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 25

  1. Targeting the DDX3/PAF1 axis enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2026.218276↗
  2. Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer. Co-author DOI 10.1038/s41698-025-01046-w↗
  3. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  4. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  5. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  6. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells. Co-author DOI 10.1016/j.neo.2022.01.002↗
  7. Reduction in O-glycome induces differentially glycosylated CD44 to promote stemness and metastasis in pancreatic cancer. First author DOI 10.1038/s41388-021-02047-2↗
  8. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  9. Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. Co-author DOI 10.1016/j.jconrel.2020.11.029↗
  10. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. First author DOI 10.1038/s41388-020-01564-w↗
  11. SUMO Modification of PAF1/PD2 Enables PML Interaction and Promotes Radiation Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1128/mcb.00135-21↗
  12. Amyloid Precursor-like Protein 2 Expression Increases during Pancreatic Cancer Development and Shortens the Survival of a Spontaneous Mouse Model of Pancreatic… Co-author DOI 10.3390/cancers13071535↗
  13. Acinar transformed ductal cells exhibit differential mucin expression in a tamoxifen-induced pancreatic ductal adenocarcinoma mouse model. Co-author DOI 10.1242/bio.052878↗
  14. PR55α regulatory subunit of PP2A inhibits the MOB1/LATS cascade and activates YAP in pancreatic cancer cells. Co-author DOI 10.1038/s41389-019-0172-9↗
  15. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. First author DOI 10.1053/j.gastro.2018.05.041↗
  16. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Co-author DOI 10.1080/15384047.2017.1416937↗
  17. Biological determinants of radioresistance and their remediation in pancreatic cancer. Co-author DOI 10.1016/j.bbcan.2017.02.003↗
  18. PR55α Subunit of Protein Phosphatase 2A Supports the Tumorigenic and Metastatic Potential of Pancreatic Cancer Cells by Sustaining Hyperactive Oncogenic Signal… First author DOI 10.1158/0008-5472.can-15-2119↗
  19. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Co-author DOI 10.18632/genesandcancer.104↗
  20. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Co-author DOI 10.1016/j.addr.2014.10.020↗
  21. Amyloid precursor-like protein 2 (APLP2) affects the actin cytoskeleton and increases pancreatic cancer growth and metastasis. Co-author DOI 10.18632/oncotarget.2990↗
  22. Targeting EGF-receptor(s) - STAT1 axis attenuates tumor growth and metastasis through downregulation of MUC4 mucin in human pancreatic cancer. Co-author DOI 10.18632/oncotarget.3286↗
  23. Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. First author DOI 10.18632/oncotarget.3912↗
  24. A concise review on the current understanding of pancreatic cancer stem cells. Co-author DOI 10.14343/jcscr.2014.2e1004↗
  25. Mucin (Muc) expression during pancreatic cancer progression in spontaneous mouse model: potential implications for diagnosis and therapy. Co-author DOI 10.1186/1756-8722-5-68↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 25 shared papers, 2012–2026 · strength 2.59
  2. Moorthy Palanimuthu Ponnusamy · 18 shared papers, 2012–2026 · strength 1.93
  3. Satyanarayana Rachagani · 16 shared papers, 2012–2024 · strength 1.41
  4. Sanchita Rauth · 7 shared papers, 2018–2026 · strength 0.96
  5. Maneesh Jain · 8 shared papers, 2012–2025 · strength 0.86
  6. Ashu Shah · 5 shared papers, 2021–2026 · strength 0.79
  7. Rama Krishna Nimmakayala · 7 shared papers, 2018–2022 · strength 0.76
  8. Lynette M. Smith · 7 shared papers, 2016–2024 · strength 0.75
  9. Kavita B. Mallya · 5 shared papers, 2020–2026 · strength 0.73
  10. Palanisamy Nallasamy · 4 shared papers, 2021–2026 · strength 0.63
  11. Jesse L. Cox · 4 shared papers, 2022–2024 · strength 0.62
  12. Pranita Atri · 5 shared papers, 2018–2024 · strength 0.59
  13. Michel M. Ouellette · 6 shared papers, 2016–2022 · strength 0.58
  14. Dhanya Haridas · 8 shared papers, 2012–2022 · strength 0.50
  15. Saravanakumar Marimuthu · 3 shared papers, 2022–2026 · strength 0.49
  16. Zahraa Wajih Alsafwani · 2 shared papers, 2025–2026 · strength 0.48
  17. Ying Yan · 5 shared papers, 2015–2022 · strength 0.45
  18. Ramakanth Chirravuri‐Venkata · 4 shared papers, 2021–2022 · strength 0.44
  19. Sushil Kumar K · 4 shared papers, 2012–2024 · strength 0.44
  20. Subodh M. Lele · 3 shared papers, 2018–2026 · strength 0.43
  21. Shailendra Kumar Gautam · 3 shared papers, 2022–2025 · strength 0.43
  22. Geoffrey A. Talmon · 4 shared papers, 2018–2022 · strength 0.42
  23. Sakthivel Muniyan · 4 shared papers, 2016–2022 · strength 0.39
  24. Imayavaramban Lakshmanan · 5 shared papers, 2015–2022 · strength 0.33
  25. Namita Bhyravbhatla · 2 shared papers, 2022–2025 · strength 0.32

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.